Therapeutic Nanocarriers in Cancer Treatment: Challenges and Future Perspective

As stated by Globocan, there were around 82 lakh cancer-related deaths and 141 lakh new cancer diagnoses worldwide in 2012. Normal genes that are expressed improperly or exhibit aberrant expression may cause neoplasia, often known as cancer. Oncogenes are mutated forms of normal cellular genes that contribute to the development of cancer. Typically, oncogenes govern cell development and differentiation. Proapoptotic genes initiate cell death and decrease the number of cells. Antioncogens, or tumour suppressor genes, regulate cell division negatively. Tumours are caused by genes that directly or indirectly control cellular proliferation or inhibition, or that govern apoptosis or any sort of cell death. As a target for the development of novel cancer treatments, tumour cell metabolism has gained substantial attention. Identification of cancer has always been a crucial aspect of diagnosis and therapy. Markers for cancer are one of the most effective approaches for recognising, diagnosing, treating, monitoring progressions, and evaluating chemical resistance. A biomarker is “a distinctive biochemical, genetic, or molecular characteristic or material that signals a particular biological state or treatment.” Tumour biomarkers are often seen in moderation in the absence of a tumour. The activation of CDKs (protein kinases) aids in the progression of cells from one phase of the cell cycle to the next. Various isoforms of CDK/cyclin complexes are capable of binding with a regulating cyclin protein. Aloisine is a potent inhibitor of CDK1, CDK 2, and CDK 5, and it has been observed that GSK3 (Glycogen synthase kinase 3) terminates cell division. Antimicrotubule medicines cause the mitotic Chk to halt the cell cycle by inhibiting microtubules. The presence of cancer cells results in enhanced cell proliferation and expansion. They can result in an absence of apoptosis and excessive cell proliferation. DNA damage or significant cellular stress might result in cell death. In cancer cells, proapoptosis is often missing or inhibited. iPSCs and cancer cells have comparable transcriptome profiles, including surface antigen markers identified by the immune system. MSCs producing IFN- accelerate the killing of tumour cells, augment NK cell activity, and decrease angiogenesis. This chapter provides an introduction of the fundamentals of cancer biology, including its characteristics, metabolic processes, and biomarkers.

Cancer is the leading cause of death worldwide. The treatment of cancer remains a challenge for medical professionals. Although various options, like chemotherapy, radiation, and surgery, are available to manage cancer, their use could be limited due to serious adverse effects. Therefore, advancements are highly essential to treat cancer properly. Nanotechnology provides new rays of hope for the effective treatment of cancer. Nanotechnology-based drug delivery carriers (NCs), such as nanoparticles, liposomes, dendrimers, polyplexes, and many more, offer treatment strategies due to their ability to target cancer cells. As these NCs target cancer cells, the exposure of other tissues to the drug is very less. Hence, these NCs exhibit fewer side effects in comparison with standard anti-cancer drugs. Here, we try to summarize a precise introduction of different NCs and their role in cancer therapy.

Cancer is one of the leading causes of death worldwide, affecting the entire world irrespective of demographic and economic variations. In the last few decades, development concerning cancer diagnosis and treatment has witnessed significant advancement but still lags far behind in terms of targeted delivery to the targeted site without much adverse effect. Changes in the structure and pathophysiology of cancer tissue, like leaky vasculature, pH, temperature, over-expression of certain receptors, etc., are being utilized for the development of different approaches of targeted drug delivery to such tissues avoiding the adverse effects associated with cancer chemotherapy. The utilization of enhanced permeability retention (EPR) and surface modification of the nano-sized formulation with different ligands, such as proteins, aptamers, antibodies, etc., are some common ways used for the above. The current chapter includes the different nano-carriers used for targeted drug delivery of medicaments to the affected site along with their surface modification which has shown their significance in the management of cancer.

Cancer is among the leading causes of death worldwide, causing a significant rise in mortality and morbidity. In this regard, nanotechnology gained a plethora of attention from researchers, owing to its nano-size and larger surface area, leading to one of the most effective drug delivery systems for chemotherapeutic agents. Indeed, they enhance the bioavailability and targeting of antitumor drugs. The formulations developed utilizing nanotechnology have been used for a long to deliver anticancer drugs. Still, they greatly suffered from several restrictions to effectively deliver the incorporated drug at the specific site. Recently, an advanced technique of developing Surface Modified Nanocarriers (SMN) addressed the shortcomings of older nanotechnology-based formulations. Specifically, ligands or other conjugates attached to the nanocarriers for targeting site-specific tumor/s have been more successful in offering site-specific drug targeting and reducing cell toxicity coupled with prolonged and sustained drug delivery.

Prostate cancer is the most common malignancy in men, with elevated morbidity and mortality. The current management, along with dope, leads to chemo defiance. On molecular imaging, many researchers have assisted with staging, restaging, early diagnosis, and, particularly, prostate cancer healing. At the site of cancer, treatment of prostate cancer, including chemo, has encountered many difficulties, such as quick clearance of dope or defiance of drug and short accumulation. Nanotechnology applications and their use in biomedicine to deliver various therapeutic carriers fitted to relieve deputy chemotherapy for cancer treatment. The tumor-targeted dope delivery-related carriers are outlined for prostate cancer healing. Among them, the developing nanotechnology has introduced several innovative new testing technologies, and medications for prostate cancer nanotechnology can significantly increase the management operation of prostate cancer by using specific physical and chemical properties, targeting techniques, or anchoring with imaging / pharmacological substances to provide an innovative theranostics device. This chapter focused on the ultra-modern outgrowth in the observation of nanomaterial and the identity of prostate cancer, including the representation of modes used to point biomolecules operationalization and the various prostate cancers along with nanoparticles, multifunctional nanoplatforms, and nano-related methods of dope delivery in the administration. 

 Breast cancer is the most common disease in women worldwide, yet current pharmacological therapy is far from ideal due to the high mortality rate among breast cancer patients. Emerging nanomedicine is a viable therapy option for breast cancer. Various potential organic and inorganic nanoparticles are promising drug nanocarriers developed for targeted delivery in breast cancer therapy over the years, with evidence established. Nanocarriers have passive and ligand-based targeting mechanisms that allow them to accumulate preferentially in breast tumours. Besides many conventional nanocarriers, polymer-based nanocarriers include the application of dendrimers, polymersomes, polymeric nanoparticles, polymer micelles, polyplexes, polymer–lipid hybrid systems, and polymer-drug/Polymer-protein conjugates to improve breast cancer therapeutic efficacy, has expanded in the recent past. However, the concept of nanocarriers with drug conjugates is constrained to the lab size. They must be scaled up to generate active-targeted nanomedicine for clinical use against breast cancer. As a result, the current chapter focuses on research that has recently been reported in the exploration of emerging nanocarriers for breast cancer therapy.

Cervical cancer (CC) is women's fourth most occurring malignancy, with a high death rate. Every CC patient is related to infection with high-risk human papillomaviruses (HPV), predominantly transmitted through sexual contact. Early diagnosis of CC helps treat surgical removal of tumours, leading to an increased patient life span. However, existing detection methods of CC, like Pap smear test, have very low sensitivity. Even though preventive vaccines for CC are doing well, they cannot protect against all HPV cancers and potential side effects. Additionally, chemotherapy for CC has had a detrimental impact because of the lack of selective tumour cell toxicity, resulting in higher adverse effects. Despite significant progress in oncology research, efficient CCs treatment is still challenging, and target-selective drug delivery formulations with a systematic release mechanism potentially avoid and reduce biotoxicity. Recent developments in nanomedicine and nanotechnology are creating more interest in developing new treatment strategies for CC treatment. Materials used in nanomedicine development are made up of synthetic or natural. These nanoparticles pointedly impacted therapeutic applications with enhanced specificity and unique personalized assets. Surface-engineered nanoparticles offer a massive possibility for compatibility with biological agents, including nucleic acids, proteins, etc. Surface fictionalization nanoparticles with targeting ligands further help in selective targeting. The present study summarizes recent advancements in surface-modified nanoparticlebased CC treatment methodologies.

Colon cancer is the third most common cause of cancer globally and leads to many deaths. Conventional chemotherapy has severe side effects and toxicities, which are significant challenges for cancer treatment. Current therapy has an essential concern of target specificity. In colon cancer, the primary concern is to deliver the drug to cancer cells in the colon in a reproducible and predictable manner. The oral route has its limitations. The drug delivered through this route gets degraded or may not be subsequently absorbed to produce the effects or lessen them before reaching the colon. Nanocarriers empowered the delivery of chemotherapeutics at specific sites and enhanced cellular penetrability. Within the organism, the cytotoxic substance will quickly accumulate. The present chapter focuses on the different nanostructures designed to deliver the drugs to treat colon cancer. 

Nowadays, Head and neck cancer is treated as a major disease worldwide. Several types of treatments are involved in this type of cancer, including immunotherapy, chemotherapy, radiation therapy, and surgery. Considering the clinical results from the past decades, these types of treatments resulted in no significant improvement in survival rates. To overcome these issues, versatile nanoparticles targeting selective tumors are considered. The targeted therapeutics based on the nanoparticle has a wide range of applications, such as photothermal therapy, radiosensitization, chemotherapeutic drug delivery, and gene splicing. In this study, we have discussed the recent advancement in targeted therapeutics based on nanoparticles for head and neck cancer. Further, we have described the targets in Head and Neck cancer and, thus, shared future perspectives.

Timely diagnosis of critical diseases, such as cancer, may help in its effective management and better survival. Several techniques like magnetic resonance imaging (MRI), computed tomography scan (CT scan), positron emission tomography (PET), photoacoustic imaging (PAI), etc. are already being used successfully, but sometimes their high cost, spatial resolution, sensitivity, and specificity (associated with the use of contrast agent) have been questionable. The distinction between benign and malignant tumours in their early stages is also a critical issue with such methods. But the use of nano-carriers for diagnostic and theranostics purposes has opened newer dimensions and provided a better understanding and visualization of the pathophysiological condition in a specific disease. There are different nanotechnologybased systems like bio-labels containing nanoparticles, nanotechnology-based microarrays, nano-bio sensors, and nanoscale optics that can be used in molecular diagnostics. Several nano-carriers, especially after their surface functionalization, are also on the floor, showing their importance in the medical diagnosis of different diseases. The current chapter deals with the importance and significance of such different nano-carriers in the development of diagnostics and theranostics.

As the nano-world continues to evolve, nanotechnology offers tremendous potential in everyday goods and creating future, environmentally friendly technologies. The advantages of nanotechnology are being realized in various areas, including engineering, medicine, biology, the environment, and communication. However, nanomaterials production is expected to increase exponentially in the next few years, resulting in significant difficulties linked to their potentially harmful impacts on human health and the environment. Furthermore, the detrimental effect of the toxicity of nanomaterials on human health is one of the industry's most critical problems as it works to exhaust its supply of nano-products. The use of nanomaterials in biological applications is the scenario with the most significant risk. Therefore, the investigation of nanotoxicity and its interaction with biomolecules continues, as are many other projects. On the other hand, assessing and validating nanotoxicity in a biological system are complex tasks. This chapter aims to examine the difficulties associated with evaluating the toxicity of nanomaterials. The evaluation of toxicity and the problems encountered in assessing the effect on biological systems are historic. The findings of in-vitro, in-vivo, and in-silico investigations on the toxicity of engineered nanomaterials are described in this chapter. The various toxicity evaluation methods each have challenges that researchers must overcome when evaluating nanomaterials in powder form, solution-based approaches, and when interacting with biological systems. The evaluation tools and characterization methods are critical in overcoming the difficulties, while the cytotoxic tests consider nanoparticle form, morphology, and size. 

Nanoparticles are expected to have a broad array of applications, ranging from delivery of therapeutic agents to bio-imaging and, quite lately, personalized treatments, due to their diameter ranging (1-100 nm), which coincides with fundamental biomolecules, such as Genetic material (DNA), significantly increased surface area (1000 m2/g), and remarkable mechanical, electrical, magnetic and photonic characteristics. The capacity to deliver targeted anti-cancer drugs to tumors, cancer detection, their capability to contain hundreds of pharmaceutical units, and their ability to resist dispersion, stability, and tolerance difficulties are all significant benefits of employing nanoparticles as a transporter for chemotherapeutics. Numerous nanomaterials and therapeutic & diagnostic compounds are now conducting clinical tests, and a couple has already received regulatory approval. The “Enhanced Permeation and Retention Effect”, a distinguishing trait of tumor cells, is used to promote controlled administration of chemotherapeutic agents. In contrast to passive targeting, depending on size, the surface of the nano-materials may be changed with a range of ligands that bind with particular receptors highly expressed on the membrane of tumor cells, resulting in precise active targeting. Yet a novel technique for site-specific delivery is using environmental stimulation like heat to a thermo-responsive apparatus to deliver a medicine encapsulated in a nanosized structure at a specified location. This chapter offers information on accepted tumour nanoparticles, such as Oncaspar, Daunoxome, Doxil, Abraxane, and DepoCyt, as well as nanoplatforms utilizing albumin nanospheres, lipoplexes, lipid nanoparticles, liposomes, micelles and gold nanoparticles, which have attained an advanced level of clinical testing.

Cancer is responsible for millions of deaths worldwide yearly. Many miles have been crossed towards the treatment of this deadly disease, however, there are still many more to explore about the occurrence, consequences, and, specifically, the accurate therapy to win over this deadly disease. Complex areas like cancer initiation, pathogenesis and the progression of cancer in the human body should be explored with better understanding to discover specific treatments against it. Currently, cancer treatments include radiation therapy, targeted therapy, surgery, chemotherapy, radiation therapy, immunotherapy, and some existing symptomatic treatments. However, the specific treatments of cancer are still a big puzzle to solve. The challenges faced in the treatment of cancer are mainly the heterogenicity of some cancers, drug resistance, late diagnosis, few treatment advances for early-stage cancer, non-selectivity of drugs towards cancer cells leading to side effects, and many more, which are still in the dark. Exploring the solution to this challenge, we need to understand the disease in totality, and understand the existing lacunas of the existing treatments too. Thus, in this chapter, we have discussed the current challenges faced in cancer therapy, followed by the future perspectives in the treatment of a wide variety of cancer.